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Aravinda Chakravarti2,*Good afternoon and welcome. I am Aravinda Chakra-
varti, and on behalf of the American Society of Human
Genetics, I have the great pleasure of introducing to
you a friend and collaborator, Dr. David Matthew
Altshuler, recipient of the 2011 Curt Stern Award. This
award is given annually by the ASHG in recognition of
major scientific achievement in human genetics in the
last ten years. In honoring David, we recognize his
contributions to three major areas: (1) making system-
atic studies of common human genetic variation
possible, (2) defining the genetic contributions to type
2 diabetes and other common disorders, and (3)
enabling a model of collaborative team science in
human genetics. David Altshuler is currently a professor
of genetics and medicine at Harvard Medical School and
deputy director and chief academic officer at the Broad
Institute.
First, a bit about Curt Stern (1902–1981): Stern was
a well-known and highly accomplished fly geneticist
before he turned his attention to human genetics. He
demonstrated physical crossover of homologous chromo-
somes in Drosophila melanogaster only weeks after McClin-
tock and Creighton had done so in maize, demonstrated
mitotic recombination resulting in somatic mosaics, and
demonstrated the mechanism of dosage compensation.
DuringWorldWar II, he led research on low-dose-radiation
safety to conclude that there was no ‘‘safe’’ threshold. He
was a pioneer of gene-regulation studies, which focused
his interests on human genetics, and a pioneer in teaching
genetics to medical students, resulting in the book ‘‘Princi-
ples of Human Genetics.’’ Curt Stern served as the 1957
ASHG president.
And now to David Altshuler: I first met David at 9:45 am
on Thursday, May 6, 1999 in Cambridge, MA. At the time,
he was a second-year postdoctoral fellow with Eric Lander
at the Whitehead Institute. He was learning human
genetics and the mapping of hereditary disorders by using
genomic tools. David arrived at the Whitehead after
completing his M.D. at Harvard University in 1994, his
Ph.D. with Connie Cepko on vertebrate rod photoreceptor
development in 1994, and his internship, residency, and
clinical fellowship in endocrinology at Massachusetts
General Hospital in 1999. I remember from our first discus-1This article is based on the address given by the author at the meeting of the In
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The Amesion that David’s interests in the genetics of common
disease were quite clear.
The scientific question in 1999—yes, 12 years
ago—was whether human disease mutations were more
like those in BRCA1 (rare) or APOE (common). When
speaking to a reporter (Steve Olson, who was writing
for the 2000 Summer Bulletin of the Howard Hughes
Medical Institute), David said, ‘‘Whether such mutations
could have been found by a dense SNP map is an area of
intense interest. What we need are more data so we can
understand the issues better and then determine how to
proceed.’’
The task of obtaining these data was muchmore compli-
cated than anyone chooses to remember. The genome
sequence was not in hand, and there were numerous
biotech companies vying to generate and make their
own genomic and SNP databases private.
It is in this background that David Altshuler began his
own studies and provided leadership for the SNP Consor-
tium that began in 1999 as a collaboration between several
companies and institutions to produce a public resource of
SNPs in the human genome. The rest is history. This led to
the intimate involvement of the NIH and the Wellcome
Trust in the International HapMap Project and later in
the 1,000 Genomes Project. David’s efforts in creating
a resource of common and rare genetic variants in humans
and the associated human-population genetics that al-
lowed interpretation of these data are of universal value
to our science.
The availability of dense catalogs of human genetic
variants has spurred numerous studies in his laboratory
and in others. The most notable studies have been those
on patterns of linkage disequilibrium within and between
human populations, on the distribution of recombina-
tion across the human genome, on the detection of
natural selection, on the estimation of group admixture,
and on numerous reconstructions of human history.
However, the studies most important to David have
been those that have allowed genetic dissection of
numerous common diseases, including his own passion,
type 2 diabetes. These studies have also brought new
controversy to our field. Why don’t these studies explain
all of a disease? Why do the genetic variants have suchternational Congress of Human Genetics on October 13, 2011 in Montreal,
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small effects? I have faith and patience that we will
answer these questions, as will David, and the answers
will come from using current clues to understand disease
mechanisms and not from merely counting. Already,
many genome-wide association studies have been very
illuminating in uncovering human biology that we
neither guessed nor could imagine. Finally, the new
common-disease studies have demanded a cultural406 The American Journal of Human Genetics 90, 405–406, March 9change in our practice of science and have required a level
of cooperation and collaboration unknown and unfa-
miliar to our field. In all of this, David Altshuler has
played a leading and remarkable role.
Ladies and gentlemen, please join the ASHG and me in
congratulating David Altshuler for significant contribu-
tions to our field of human genetics and as the 2011 Curt
Stern awardee., 2012
